Traditional biologics, predominantly monoclonal antibodies (mAbs), are continuing to see strong market demand, but despite the robust pipeline for mAb development, there are bottlenecks that still exist. In this article, Seokjin Chang, our Director of Market Intelligence, identifies where the bottlenecks occur and how the investments CDMOs bring to the process can allow biopharma and biotech companies to avoid them. 

Read more (Page.16)